Azafaros is developing new treatment options to help patients with rare metabolic disorders. Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential. 

Biotechnology

Azafaros

Stefano Portolano

Dr. Kyung-Jae Na

Silvia Ragno

Christian Freitag

Anke Arnold-Tugulu

Gisela Linthorst

Laura López de Frutos

Kyle Landskroner

Business Development and Strategy

Clinical Operations and Development

Leadership Team

Teams at Azafaros

Business Development and Strategy

Clinical Operations and Development

Leadership Team